Skip to main
ASMB

Assembly Biosciences (ASMB) Stock Forecast & Price Target

Assembly Biosciences (ASMB) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Assembly Biosciences is a promising clinical-stage biotechnology company with a diverse pipeline of innovative therapies for viral infections, including recurrent genital herpes, hepatitis delta virus, and hepatitis B virus. The company's strong balance sheet and ongoing partnerships with industry leaders like Gilead offer significant potential for long-term success, while the recent opt-in decision from Gilead for the HSV program further validates the company's innovative approach. Additionally, the company's high-profile collaborations and diverse portfolio add significant optionality for future growth and positive returns for shareholders.

Bears say

Assembly Biosciences is still in the clinical stage and has yet to produce any products for commercialization, making it a risky investment. While the company's pipeline shows potential, competition already exists in the HSV market and their products may not be able to compete with established treatments. Additionally, without any approved products, it is difficult to accurately predict potential revenue and market share for Assembly Biosciences.

Assembly Biosciences (ASMB) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assembly Biosciences (ASMB) Forecast

Analysts have given Assembly Biosciences (ASMB) a Buy based on their latest research and market trends.

According to 4 analysts, Assembly Biosciences (ASMB) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assembly Biosciences (ASMB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.